Janine D'amico
Adult Health · Commack, NYNPI 1851840540
Payments from drug & device makers
Across 355 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novo Nordisk$826
- Boehringer Ingelheim$756
- Lilly USA, LLC$741
- Xeris Pharmaceuticals, Inc.$506
- AstraZeneca$353
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,460100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 114 | $1,517 |
| Novo Nordisk | 56 | $826 |
| Boehringer Ingelheim | 32 | $756 |
| Lilly USA, LLC | 33 | $741 |
| Xeris Pharmaceuticals, Inc. | 23 | $506 |
| AstraZeneca(2 entities) | 20 | $353 |
| Antares Pharma, Inc. | 11 | $262 |
| Amneal Pharmaceuticals LLC | 10 | $236 |
| Corcept Therapeutics | 7 | $190 |
| Dexcom, Inc. | 7 | $154 |
| Madrigal Pharmaceuticals | 4 | $98 |
| Amryt Pharma Holdings Ltd | 4 | $89 |
| Pfizer | 3 | $73 |
| Insulet Corporation | 3 | $66 |
| Tandem Diabetes Care, Inc. | 3 | $62 |
| Kyowa Kirin, Inc. | 2 | $55 |
| Merck | 3 | $54 |
| Amgen | 3 | $49 |
| IBSA Pharma Inc. | 2 | $44 |
| Ascendis Pharma Endocrinology Inc | 2 | $44 |
| Endo Pharmaceuticals Inc. | 2 | $40 |
| Halozyme Inc | 1 | $31 |
| Boston Scientific | 1 | $28 |
| Averitas Pharma Inc. | 1 | $25 |
| Chiesi USA, Inc. | 1 | $23 |
| Mannkind Corporation | 1 | $23 |
| AbbVie | 1 | $23 |
| Cequr Corporation | 1 | $21 |
| Verity Pharmaceuticals Inc. | 1 | $20 |
| Clarus Therapeutics Inc. | 1 | $19 |
| Acerus Pharmaceuticals Corporation | 1 | $19 |
| Vistapharm, Inc. | 1 | $15 |
How this compares
$6,460 in reported general payments places this provider in the 90th percentile of 3,828 adult health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 215 | $403,810 |
| MounjaroTirzepatide | 146 | $248,369 |
| JardianceEmpagliflozin | 156 | $229,728 |
| TrulicityDulaglutide | 100 | $189,875 |
| FarxigaDapagliflozin Propanediol | 55 | $77,934 |
| RybelsusSemaglutide | 45 | $73,234 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $43,137 |
| ProliaDenosumab | 16 | $27,663 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 51 | $25,559 |
| TradjentaLinagliptin | 28 | $24,771 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $23,181 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $20,687 |
| Gvoke Hypopen 2-PackGlucagon | 11 | $11,464 |
| Testosterone | 24 | $10,621 |
| Metformin Hcl ErMetformin Hcl | 454 | $8,608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $826 | $477,044260 claims |
| Lilly USA, LLCMounjaro, Trulicity | $741 | $438,243246 claims |
| Boehringer IngelheimJardiance, Tradjenta | $756 | $254,499184 claims |
| AstraZenecaFarxiga | $353 | $77,93455 claims |
| AmgenProlia | $49 | $27,66316 claims |
| MerckJanumet Xr | $54 | $20,68715 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $236 | $4,401354 claims |
| AbbVieSynthroid | $23 | $3,61050 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,828 adult health providers in New York.
Other adult health in Commack
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Katelyn McCormackAmherst$201K
- Mary CiechoskiBuffalo$200K
- Patricia LorussoLancaster$161K
- Jennifer FioriniGlens Falls$151K
- Tia AlbroRochester$142K
- Maria Gigante-BaggettEast Syracuse$92K
- Jane PattersonRochester$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.